Concepedia

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

Arlene O. Siefker‐Radtke, Nobuaki Matsubara, S.H. Park, Robert Huddart, Earle F. Burgess, Mustafa Özgüroğlu, Begoña P. Valderrama, Brigitte Laguerre, Umberto Basso, Spyros Triantos,

Annals of Oncology · 2023 · 80 citations · 9 references

DOIFull text

Open access

Concepts

References

9

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles et al. · The Lancet · 2016 · 3.7K citations

, , +13

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

Joaquim Bellmunt, Ronald de Wit, David J. Vaughn et al. · New England Journal of Medicine · 2017 · 3.4K citations · Full text

, , +17

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

Yohann Loriot, Andrea Necchi, Se Hoon Park et al. · New England Journal of Medicine · 2019 · 1.4K citations · Full text

, , +15

Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986

Maria De Santis, Joaquim Bellmunt, Graham M. Mead et al. · Journal of Clinical Oncology · 2011 · 773 citations · Full text

, , +13

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 648 citations · Full text

, , +11